Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Ovarian EndometriomaEndometrioma

Interventions

DRUG

Estetrol/Drospirenone

6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration

Trial Locations (1)

RECRUITING

McGill University Health Center, Montreal

All Listed Sponsors

lead

Andrew Zakhari

OTHER

NCT05837624 - Estetrol/Drospirenone to Reduce the Average Size of Endometriomas | Biotech Hunter | Biotech Hunter